TITLE

Evaluating two analgesic options for dogs undergoing orthopedic surgery

AUTHOR(S)
Harari, Joseph
PUB. DATE
September 2005
SOURCE
Veterinary Medicine;Sep2005, Vol. 100 Issue 9, p641
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the results of a clinical trial on two analgesic options for dogs undergoing orthopedic surgery. Surgical procedures performed to evaluate any adverse drug reactions.
ACCESSION #
18379494

 

Related Articles

  • WOUND INFECTION AFTER THERAPEUTIC TOOTH EXTRACTION WITH AND WITHOUT ANTIBIOTICS. WAHAB, P. U. ABDUL; MADHU LAXMI, M.; SENTHIL NATHAN, P. // International Journal of Pharma & Bio Sciences;Oct-Dec2013, Vol. 4 Issue 4, pB-1277 

    An analgesics and antibiotics are generally prescribed following extraction of the teeth. However, the role of antibiotics is controversial in clean contaminated wounds. Most of the oral surgeon's advice antibiotics for extraction of non-infected teeth and this causes side effects. The purpose...

  • Labopharm completes enrollment for US phase III clinical trials.  // PharmaWatch: CNS;July 2003, Vol. 2 Issue 7, p22 

    Reports on the completion of the clinical trial for analgesic tramadol by Labopharm Inc. in the U.S. Assessment on the side effects of the drugs; Use of the drugs in reducing the risks of osteoarthritis; Level of safety.

  • A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee. Bar-Or, David; Salottolo, Kristin M.; Loose, Holli; Phillips, Matthew J.; McGrath, Brian; Wei, Nathan; Borders, James L.; Ervin, John E.; Kivitz, Alan; Hermann, Mark; Shlotzhauer, Tammi; Churchill, Melvin; Slappey, Donald; Clift, Vaughan // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Objective: The Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A) is being investigated as a treatment for knee pain from osteoarthritis. Methods: This was a multicenter randomized, vehicle-controlled, double-blind, parallel study designed to evaluate the safety and efficacy of...

  • Two formulations for relief of acute and extended pain.  // Cortlandt Forum;Oct2006, Vol. 19 Issue 10, p22 

    The article offers information about Opana ER, an immediate-release and extended-release tablets, from Endo Pharmaceuticals. The drug is indicated for use to treat acute moderate to severe pain following abdominal and orthopedic surgery. Opana also potentiates central nervous system depression...

  • Continuous i.v. infusion of remifentanil and intraosseous lidocaine provide better analgesia than intraosseous lidocaine alone in percutaneous vertebroplasty of osteoporotic fractures. Dauri, M.; Coniglione, F.; Faria, S.; Fiori, R.; Frunzo, F.; Massari, F.; Simonetti, G.; Sabato, A. F.; Masala, S. // BJA: The British Journal of Anaesthesia;Dec2009, Vol. 103 Issue 6, p901 

    The article discusses a placebo-controlled randomized clinical trial which indicates that continuous intravenous infusion of remifentanil and intraosseous lidocaine (ILR) provide better analgesia compared to intraosseous lidocaine (IL) alone in percutaneous vertebroplasty (PV) of osteoporotic...

  • Drug Safety Fears Threaten Research. Wechsler, Jill // Applied Clinical Trials;Feb2005, Vol. 14 Issue 2, p26 

    This article reports that the growing alarm over harmful side effects related to a number of popular prescription drugs is affecting a range of issues of critical importance for clinical trial sponsors and investigators. The U.S. National Institutes of Health recently halted important clinical...

  • FDA Puts Hold on Phase II AeroLEF Study; YM Slides.  // BioWorld Today;1/18/2008, Vol. 19 Issue 13, p2 

    The article reports that the U.S. Food & Drug Administration (FDA) placed a clinical hold on a Phase II study of AeroLEF in acute pain. The FDA, which previously cleared YM Biosciences Inc. to begin Phase II development in June 2008, requested additional safety information, specifically data...

  • An update on analgesics. Power, I. // BJA: The British Journal of Anaesthesia;Jul2011, Vol. 107 Issue 1, p19 

    Recent introduction of new analgesics into the clinic is best described as a slow process with activity classified into two main areas: improving analgesic efficacy/potency and reducing side-effect profile. This review article describes some of the recent advances with an emphasis on use in the...

  • Nektar Therapeutics enrolls first patient in Phase II chronic pain study.  // PharmaWatch: CNS;Sep2012, Vol. 11 Issue 9, p15 

    The article reports on the enrollment of Nektar Therapeutics' first patient in a Phase II clinical study of NKTR-181, a new opioid analgesic candidate. The opioid analgesic is designed to have a slow rate of entry into the brain to reduce the attractiveness of the molecule as a target of abuse...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics